Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5063654 | 0.93 | CNR1 (0.31) | CNR1CNR2SLC2A1 | |
| SCHEMBL5067549 | 0.92 | CNR2 (0.34) | CNR1CNR2SLC2A1 | |
| SCHEMBL5063624 | 0.90 | CNR1 (0.31) | CNR1 | |
| SCHEMBL5062394 | 0.90 | LMNA (0.35) | CNR1CNR2SLC2A1 | |
| SCHEMBL5058490 | 0.90 | ALDH1A1 (0.34) | CNR1CNR2SLC2A1 | |
| SCHEMBL5062984 | 0.88 | CNR1 (0.33) | CNR1CNR2SLC2A1 | |
| SCHEMBL5067636 | 0.85 | CACNA1B (0.41) | SLC2A1 | |
| SCHEMBL5062673 | 0.85 | TP53 (0.37) | TP53TSHR | |
| SCHEMBL5062946 | 0.83 | ATG4B (0.39) | — | |
| SCHEMBL5066332 | 0.73 | CDK1 (0.36) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | CNR1 4419/4885CNR2 4484/4885SLC2A1 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.